版本:
中国

BRIEF-Theravance Biopharma reports positive clinical response rates for patients in TOUR observational patient registry

April 24 Theravance Biopharma Inc:

* Theravance Biopharma reports positive clinical response rates for patients in TOUR™ observational patient registry in several presentations at ECCMID 2017

* Theravance Biopharma inc says vibativ was generally well tolerated in these patients with adverse event type

* Theravance Biopharma says there were six deaths within 28 days of first vibativ dose and two patients discontinued treatment due to an adverse event

* Theravance Biopharma -of 36 patients, 8 patients had at least 1 adverse event & 4 patients had at least one serious adverse event treated with vibativ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐